Drug Information

Drug General Information
Drug ID
D0RO8H
Former ID
DIB004103
Drug Name
AC-262271
Synonyms
IOP lowering (glaucoma), Allergan; Muscarinic M1 agonists (pain, glaucoma), ACADIA/Allergan
Indication Glaucoma [ICD9: 365; ICD10:H40-H42] Phase 1 [549229]
Company
Acadia pharmaceuticals
Target and Pathway
Target(s) Muscarinic acetylcholine receptor M1 Target Info Agonist [550343]
KEGG Pathway Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
PI3K-Akt signaling pathway
Cholinergic synapse
Regulation of actin cytoskeleton
PANTHER Pathway Alzheimer disease-amyloid secretase pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Reactome Muscarinic acetylcholine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
Regulation of Actin Cytoskeleton
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Secretion of Hydrochloric Acid in Parietal Cells
GPCR ligand binding
GPCR downstream signaling
References
Ref 549229Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033965)
Ref 550343Phase I clinical trial of muscarinic agonist (AC-262271) for treating glaucoma. Acadia Pharmaceuticals.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.